RE: Buying opportunity11 Jan 2019 07:07
The hope is that Parsortix will one day be used to routinely monitor cancer patients and help determine if tumours in the body of otherwise healthy people are malignant or benign.
“I’m hoping this work in Basel might do the same for cancer as anti-retroviral drugs did for HIV. It is absolutely amazing news for us and has a huge impact on our revenue potential," said Mr Newland.